Overview
Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets
Status:
Completed
Completed
Trial end date:
2012-11-01
2012-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of this trial is to establish bioequivalence of two FDC tablets and the single tablets when administered together after a high fat high caloric meal.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Boehringer IngelheimTreatments:
Empagliflozin
Metformin
Criteria
Inclusion criteria:1. Healthy male and female subjects
Exclusion criteria:
1. Any relevant deviation from healthy conditions